NO914002L - Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister - Google Patents

Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister

Info

Publication number
NO914002L
NO914002L NO91914002A NO914002A NO914002L NO 914002 L NO914002 L NO 914002L NO 91914002 A NO91914002 A NO 91914002A NO 914002 A NO914002 A NO 914002A NO 914002 L NO914002 L NO 914002L
Authority
NO
Norway
Prior art keywords
hydroxylkylqinolic
seated
acids
procedure
preparation
Prior art date
Application number
NO91914002A
Other languages
English (en)
Norwegian (no)
Other versions
NO914002D0 (no
Inventor
Michel L Belley
Serge Leger
Patrick Roy
Yi Bin Xiang
Marc Labelle
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO914002D0 publication Critical patent/NO914002D0/no
Publication of NO914002L publication Critical patent/NO914002L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
NO91914002A 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister NO914002L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59684490A 1990-10-12 1990-10-12

Publications (2)

Publication Number Publication Date
NO914002D0 NO914002D0 (no) 1991-10-11
NO914002L true NO914002L (no) 1992-04-13

Family

ID=24388953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914002A NO914002L (no) 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister

Country Status (16)

Country Link
US (1) US5428033A (zh)
EP (1) EP0480716A1 (zh)
JP (1) JP2538155B2 (zh)
KR (1) KR920008004A (zh)
CN (1) CN1061408A (zh)
AU (1) AU639611B2 (zh)
CA (1) CA2053216C (zh)
CS (1) CS309391A3 (zh)
FI (1) FI914797A (zh)
HU (1) HUT61980A (zh)
IE (1) IE913611A1 (zh)
IL (1) IL99725A0 (zh)
MX (1) MX9101557A (zh)
NO (1) NO914002L (zh)
PT (1) PT99212B (zh)
ZA (1) ZA918120B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US6696466B1 (en) * 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
WO2002064136A2 (en) * 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
DE60219595T2 (de) 2001-01-26 2008-01-10 Chugai Seiyaku K.K. Verfahren zur behandlung von erkrankungen mit malonyl coa-decarboxylase-inhibitoren
CN101596191B (zh) * 2001-01-26 2011-06-15 中外制药株式会社 用作代谢调节剂的丙二酰基辅酶a脱羧酶抑制剂
US7709510B2 (en) * 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
SI1370260T1 (sl) 2001-02-20 2011-02-28 Chugai Pharmaceutical Co Ltd Azoli kot inhibitorji malonil-CoA dekarboksilaze, uporabni kot metabolični modulatorji
WO2005011670A1 (en) * 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
ATE400272T1 (de) * 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
US7285562B2 (en) * 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
JP4773960B2 (ja) * 2003-08-01 2011-09-14 中外製薬株式会社 マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノグアニジン型アゾール化合物
ES2371549T3 (es) * 2003-10-10 2012-01-05 Synthon B.V. Montelukast en estado sólido.
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
CA2563776A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
ES2358923T3 (es) * 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
WO2009001374A2 (en) * 2007-06-25 2008-12-31 Aptuit Laurus Pvt Ltd Preparation of ethyl-3'-[((7-chloro-2-quinolinyl)ethenyl)phenyl]-3-oxopropanoate, a key intermediate for montelukast sodium
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
JP6038914B2 (ja) * 2011-07-26 2016-12-07 スン プハルマ アドバンセド リサーチ カンパニー リミテド キノリン−、キノキサリン、又はベンゾチアゾールベースのシステイニルロイコトリエンアンタゴニスト（ｌｔｃ４）
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4325961A (en) 1977-06-01 1982-04-20 Merck & Co., Inc. Fluorinated amino acids
PT68303A (en) 1977-07-26 1978-08-01 Merck & Co Inc Process for the preparation of dibenzo/b,f/thiepin
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
PH16099A (en) 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
GB2058785B (en) 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
US4237160A (en) 1979-11-27 1980-12-02 Merck Sharp & Dohme (I.A.) Corp. 3-Hydroxymethyldibenzo[b,f]thiepins as prostaglandin antagonists
DE3175201D1 (en) 1980-04-30 1986-10-02 Merck & Co Inc Aminothiadiazoles as gastric secretion inhibitors
US4394508A (en) 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
EP0056172B1 (en) 1981-01-09 1985-04-03 FISONS plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
DE3265715D1 (en) 1981-03-24 1985-10-03 Fisons Plc Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them
IL69691A (en) 1982-09-23 1988-01-31 Merck Frosst Canada Inc Leukotriene antagonists,their preparation and pharmaceutical compositions containing them
EP0106565B1 (en) 1982-09-30 1986-09-10 Merck Frosst Canada Inc. Leukotriene antagonists, their production, and compositions containing them
NZ206795A (en) 1983-01-21 1987-08-31 Merck Frosst Canada Inc Phenothiazines, analogues and pharmaceutical compositions
DE3479397D1 (en) 1983-10-05 1989-09-21 Merck Frosst Canada Inc Benzoûa¨phenothiazines and hydro-derivatives and pharmaceutical compositions containing them
EP0138481B1 (en) 1983-10-05 1991-06-26 Merck Frosst Canada Inc. Leukotriene biosynthesis inhibitors
ES537162A0 (es) 1983-10-31 1985-12-01 Merck Frosst Canada Inc Una composicion farmaceutica
DK282986A (da) 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
DE3700732A1 (de) * 1987-01-13 1988-07-21 Boehringer Mannheim Gmbh Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
US5104882A (en) * 1987-11-25 1992-04-14 Merck Frosst Canada, Inc. Diarylstrylquinoline diacids and pharmaceutical compositions thereof
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
MX9101557A (es) 1994-05-31
JP2538155B2 (ja) 1996-09-25
JPH06206868A (ja) 1994-07-26
US5428033A (en) 1995-06-27
AU8579691A (en) 1992-04-16
HUT61980A (en) 1993-03-29
PT99212B (pt) 1999-04-30
KR920008004A (ko) 1992-05-27
FI914797A0 (fi) 1991-10-11
CN1061408A (zh) 1992-05-27
IE913611A1 (en) 1992-04-22
CA2053216A1 (en) 1992-04-13
CA2053216C (en) 2003-04-08
CS309391A3 (en) 1992-05-13
PT99212A (pt) 1992-09-30
FI914797A (fi) 1992-04-13
ZA918120B (en) 1992-06-24
AU639611B2 (en) 1993-07-29
HU913216D0 (en) 1992-01-28
NO914002D0 (no) 1991-10-11
IL99725A0 (en) 1992-08-18
EP0480716A1 (en) 1992-04-15

Similar Documents

Publication Publication Date Title
NO914002L (no) Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister
NO904987D0 (no) Fremgangsmaate for fremstilling av indolderivater.
NO902003D0 (no) Fremgangsmaate for fremstilling av n-heteroaryl-4-quinolinaminer.
NO900774L (no) Fremgangsmaate for fremstilling av polyamider.
NO901554L (no) Fremgangsmaate for fremstilling av dinatrium-cefodizim.
NO904285L (no) Fremgangsmaate for fremstilling av substituerte karboksytetrahydroisokinoliner.
NO903431D0 (no) Fremgangsmaate for fremstilling av kromanderivater.
NO910608L (no) Fremgangsmaate for fremstilling av tricykliske leukotrien-antagonister.
NO903275L (no) Fremgangsmaate for fremstilling av kromanderivater.
NO905377L (no) Fremgangsmaate for fremstilling av glycerolderivater.
NO903043L (no) Fremgangsmaate for fremstilling av kromanderivater.
NO903147D0 (no) Fremgangsmaate for fremstilling av hydrolyserte vegetabilske proteiner.
NO903207L (no) Fremgangsmaate for fremstilling av halogenaminoaromatiske derivater.
NO901690L (no) Fremgangsmaate til fremstilling av substituerte azetidinylisotiazolpyridon-derivater.
NO902762D0 (no) Fremgangsmaate for fremstilling av 5-fenyl-2-furan derivater.
NO901067D0 (no) Fremgangsmaate for fremstilling av tiofener.
NO904060D0 (no) Fremgangsmaate for fremstilling av substituerte dibenzofuraner.
NO900969L (no) Fremgangsmaate for fremstilling av n-allymetatrifluormetylanilin.
NO901687D0 (no) Fremgangsmaate for fremstilling av thiazetokinolin-3-carboxylsyrederivater.
NO905047D0 (no) Fremgangsmaate for fremstilling av selenofenderivater.
NO904588L (no) Fremgangsmaate til fremstilling av diazinylpiperidin-derivater
NO892940D0 (no) Fremgangsmaate for fremstilling av detergent-blandinger.
NO904070D0 (no) Fremgangsmaate for fremstilling av alkanfenoner.
NO930481D0 (no) Fremgangsmaate for fremstilling av klormetaner
NO932717D0 (no) Fremgangsmaate for fremstilling av stoept silikatbasert vaskemiddel